Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Pimlott, Sally L.; Piggott, Margaret A.; Owens, Janel E.; Greally, Elizabeth; Court, Jennifer A.; Jaros, Evelyn; Perry, Robert H.; Perry, Elaine K.; Wyper, David J.

doi:10.1038/sj.npp.1300302

Cited by 152 publications

(122 citation statements)

References 52 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…These findings have been confirmed in studies using the recently developed ␣4␤2-specific radioligand, 5-125 I-A-85380, which shows reduced expression of ␣4␤2 in the caudate striatum and entorhinal cortex (Pimlott et al, 2004). This same ligand has also been used to demonstrate loss of ␣4␤2 in frontal lobe, striatum, right medial temporal lobe, and pons of patients with AD using single-photon-emission computed tomography (SPECT) (O'Brien et al, 2007).…”

Section: A Expression Of ␣4␤2 and ␣7 Nicotinic Acetylcholine Receptomentioning

confidence: 75%

Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

et al. 2009

View full text Add to dashboard Cite

Section: A Expression Of ␣4␤2 and ␣7 Nicotinic Acetylcholine Receptomentioning

confidence: 75%

Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

et al. 2009

View full text Add to dashboard Cite

“…37 The impact on cortical cholinergic receptors is similar in PDD and DLB, with increased muscarinic binding 38 and a considerable reduction in nicotinic binding, although in the insular cortex the reductions were more marked in PDD than in DLB. 39 Further studies indicate a possible association between impaired consciousness and upregulation of nicotinic α4β2 nicotinic receptors in the temporal cortex. In a study comparing muscarinic receptor binding within the striatum in DLB and PD patients, M1 receptors were significantly reduced in DLB but not in PD patients.…”

Section: 30mentioning

confidence: 95%

“…39 Further studies indicate a possible association between impaired consciousness and upregulation of nicotinic α4β2 nicotinic receptors in the temporal cortex. In a study comparing muscarinic receptor binding within the striatum in DLB and PD patients, M1 receptors were significantly reduced in DLB but not in PD patients.…”

mentioning

confidence: 95%

Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity?

Aarsland

Ballard

Halliday

2004

J Geriatr Psychiatry Neurol

184

102

View full text Add to dashboard Cite

Dementias associated with cortical Lewy bodies are traditionally classified as dementia with Lewy bodies (DLB), characterized by parkinsonism, visual hallucinations and cognitive fluctuations, 1 or Parkinson's disease with dementia (PDD). Overall, DLB accounts for about 20% of late-onset dementia cases, 1 and dementia develops in the majority of cases with a diagnosis of PD. 2 As outlined below, there are clinical and neurobiological similarities between DLB and PDD patients. The distinction between the conditions as operationally defined within the standardized clinical criteria depends entirely on the duration of parkinsonism prior to dementia. The consensus criteria for a clinical diagnosis of DLB state that a diagnosis cannot be made if parkinsonian symptoms developed more than 1 year before the onset of dementia (although proposed recent changes to the criteria may alter this to making the diagnosis according to whether parkinsonism or cognitive impairment arises first). This raises several key conceptual questions; for example, are these conditions distinct or part of the same spectrum? If they are distinct conditions, is an arbitrary cutoff (either 1 year or which symptom presents first) a meaningful distinction between clinical entities with different clinical presentations? Addressing these issues is critical to taking forward our understanding of this spectrum of conditions, establishing biological markers, determining prognostic indicators, and, most important, designing appropriate intervention studies and developing treatment paradigms across the dementias associated with cortical Lewy bodies. In the current article, key issues pertaining to DLB and PDD are reviewed, and the similarities and differences in the clinical profile (cognitive deficits, neuropsychiatric symptoms, and parkinsonism), imaging, genetic predisposition, neurochemistry, and neuropathology are discussed to enable some conclusions about the relationship of the 2 conditions and to offer some suggestions for critical future research. Direct comparative studies of patients with PDD and DLB are necessary to explore the relationship between these 2 syndromes. We searched the MEDLINE using Parkinson* disease and dementia Are Parkinson's Disease With Dementia and Dementia With Lewy Bodies the Same Entity?Dag Aarsland, MD, PhD, C. G. Ballard, MD, MRCPsych, and Glenda Halliday, PhD ABSTRACTThe diagnosis of Parkinson's disease with dementia (PDD) or dementia with Lewy bodies (DLB) is based on an arbitary distinction between the time of onset of motor and cognitive symptoms. These syndromes share many neurobiological similarities, but there are also differences. Deposition of beta-amyloid protein is more marked and more closely related to cognitive impairment in DLB than PDD, possibly contributing to dementia at onset. The relatively more severe executive impairment in DLB than PDD may relate to the loss of frontohippocampal projections in DLB. Visual hallucinations and delusions associate with more abundant Lewy body pathology in temporal c...

show abstract

“…Another crucial problem with 2-[ 18 F]FA and 6-[ 18 F]FA is relatively low binding potential (BP) in extrathalamic regions (BP ≤ 0.6-0.8), including the cortex, which has a lower nAChR density. Altered densities of cortical and striatal nAChRs in neurodegenerative diseases (Pimlott et al, 2004) and schizophrenia (Ochoa & LasaldeDominicci, 2007) illustrates the importance of imaging extrathalamic nAChRs. A variety of radioligands with fast regional brain kinetics have been presented in nonhuman primates and pigs.…”

Section: Positron Emission Tomography Ligands For 42 Nachrsmentioning

confidence: 99%

Nicotinic Acetylcholine Receptor Alterations in Autism Spectrum Disorders – Biomarkers and Therapeutic Targets

Anand¹,

Amici²,

Ponath³

et al. 2011

Autism - A Neurodevelopmental Journey From Genes to Behaviour

View full text Add to dashboard Cite

Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Cited by 152 publications

References 52 publications

Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity?

Nicotinic Acetylcholine Receptor Alterations in Autism Spectrum Disorders – Biomarkers and Therapeutic Targets

Contact Info

Product

Resources

About